(Q40282075)

19 September 2017

title

Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. (English)

1 reference

19 September 2017

Soars MG

1

1 reference

19 September 2017

Grime K

series ordinal

2

1 reference

19 September 2017

Riley RJ

series ordinal

3

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

36

1 reference

19 September 2017

issue

4

1 reference

19 September 2017

page(s)

287-299

1 reference

Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

In vitro and pharmacophore insights into CYP3A enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Does the CYP3A5*3 polymorphism affect in vivo drug elimination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

A significant drug-metabolizing role for CYP3A5?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

The human hepatic cytochromes P450 involved in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250500446208

10.1080/00498250500446208

21 January 2018

Identifiers

DOI

1 reference

19 September 2017

1 reference